Chemoprotection of haematopoietic stem cells (HSCs) by gene therapeutic transfer of drug-resistance genes represents the encouraging approach to prevent myelosuppression, which is one of the most severe side effects in tumor therapy. Thus, we cloned and evaluated six different bicistronic lentiviral SIN vectors encoding two transgenes, MGMT P140K (an O 6 -benzylguanineresistant mutant of methylguanine-DNA methyltransferase) and MDR1 (multidrug resistance 1), using various linker sequences (IRESEMCV, IRESFMDV and 2A-element of FMDV (F2A)). Expression of both transgenes in HL-60 and in K562 cells was assayed by quantitative real-time PCR. Combination therapy with ACNU plus paclitaxel in HL-60 cells and with carmustin (BCNU) plus doxorubicin in K562 cells resulted in the most significant survival advantage of cells transduced with the lentiviral vector HR'SIN-MGMT P140K -F2A-MDR1 compared with untransduced cells. In human HSCs, overexpression of both transgenes by this vector also caused significantly increased survival and enrichment of transduced cells after treatment with BCNU plus doxorubicin or temozolomide plus paclitaxel. In summary, we could show significant chemoprotection by overexpression of MDR1 and MGMT P140K with a lentiviral vector using the F2A linker element in two different haematopoietic cell lines and in human primary HSCs with various combination regimens. Consequently, we are convinced that these in vitro investigations will help to improve combination chemotherapy regimens by reducing myelotoxic side effects and increasing the therapeutic efficiency. 
INTRODUCTION
The effect of systemic application of chemotherapeutics is not only restricted to tumor cells but is also accompanied by a considerable damage of normal tissue cells and is often causal for severe myelosuppression. 1 The repeated damage of primitive haematopoietic stem cells (HSCs) results in profound and sustained bone marrow aplasias. Such a bone marrow suppression or myelotoxicity is followed by bacterial, viral and mycotic infections. These infections and the protracted treatment result in a delay of the timely therapy (with the risk of a tumor progress) or even in an abortion of the therapy. A dose reduction of 20% results in a decreased cure rate on average of up to 50%. 2 Moreover, the economical aspect of myelosuppression is very important, for example, hospitalization due to febrile neutropenia led to expenses of more than one billion US dollars during a 5-year period. 3 Thus, an approach for protection of HSCs would be extremely beneficial for the successful treatment of the tumor patient. A very interesting chemoprotective strategy is the gene therapeutic transfer of a resistance gene into HSCs. For this reason, different genes have already been evaluated. 4, 5 Owing to combination therapies during tumor treatment the simultaneous transfer of two resistance genes would be advantageous to protect healthy cells against different classes of chemotherapeutic drugs.
Especially the two genes MDR1 and MGMT are of particular interest. MDR1 is an efflux pump of various standard chemotherapeutics like doxorubicin, paclitaxel or vincristin; 6, 7 MGMT removes alkyl groups from the nucleotide base guanine added by agents like carmustin (BCNU) or temozolomide (TMZ). 8, 9 Combinations of both types of chemotherapeutic drugs have been applied as standard treatment regimens for various tumor entities, however, frequently evoking myelosuppression as a doselimiting side effect. [10] [11] [12] Various attempts were shown for chemoprotection of HSCs by retroviral transfer of MDR1 or MGMT. Gammaretroviral transfer of MDR1 into murine HSCs resulted in efficient chemoprotection against paclitaxel 13 or taxol. [14] [15] [16] These promising results could not be repeated in marmosets or dogs treated either with paclitaxel 17 or docetaxel. 18 Most of the attempts in humans failed due to low levels of gene transfer or transgene expression. [19] [20] [21] Only the results of a study in Japan suggested a chemoprotective effect in two breast cancer patients after treatment with docetaxel.
According to MGMT, successful chemoprotection of HSCs against treatment with BCNU or TMZ after lentiviral transgene expression could be shown in canine models. 23, 24 As for MDR1 no chemoprotection could be achieved in nonhuman primates and in humans. 25, 26 Simultaneous gammaretroviral transfer of both resistance genes was performed only in vitro into cell lines or primary hematopoietic cells to assay for chemoprotection against various combinations of certain MDR1 substrate drugs with alkylating agents. [27] [28] [29] [30] However, we showed for the first time efficient chemoprotection of HSCs using a third-generation lentiviral SIN vector for transfer of MDR1 and the MGMT P140K mutant. 31 This special form of MGMT is resistant against O 6 -benzylguanine (O 6 -BG), 32 an inhibitor of wild-type MGMT, which can be applied to block MGMT activity in tumor cells rendering them sensitive for an alkylating agent while HSCs expressing the mutant form are efficiently protected. Transduction of myeloid cells or HSCs with our bicistronic vector (HR'SIN-MDR1-IRESEMCV-MGMT P140K ) with MGMT P140K at the second position resulted in less efficient protection against alkylating agents than against MDR1 substrates.
31 This might be due either to the position of the transgene or to the linker element used. For internal ribosome entry sites (IRES) elements it was shown that the expression level of the second cistron is often reduced by about 50-90% of the level of the first cistron. 33 Another possible linker element is the 2A element, a sequence of 57 bp in picornaviruses like foot-andmouth disease virus (FMDV) or equine rhinitis A virus. 34 Using this linker sequence, the upstream transgene must be devoid of a stop codon. Thus, the mRNA is translated into one polypeptide, which is subsequently autocatalytically cleaved directly in front of the last amino acid of the 2A-element (a prolin). 35 Cleavage activity in recombinant vectors has been improved by using longer versions of 2A-elements containing extra amino acids from the FMDV protein 1D, immediately upstream of 2A. [35] [36] [37] Thus, equimolar expression of both recombinant proteins will be accomplished in contrast to the use of IRES-elements.
The aim of this study was to evaluate the chemoprotective potential of six bicistronic vectors using three different linker elements for simultaneous expression of both transgenes MDR1 and MGMT P140K . For this reason, we quantified the expression rates of both vector-derived transgenes contrasting their position and the various linker elements. We analyzed the chemoprotection in the hematological cell lines K562 and HL-60 and in primary human HSCs against different combinations of chemotherapeutic drugs that are clinically used.
MATERIALS AND METHODS Drugs
ACNU (nimustine; Baxter, Unterschleiheim, Germany) was solubilized in aqua dest, BCNU (Bristol-Myers Squibb, Munich, Germany) in 100% ethanol, O 6 -BG (Sigma-Aldrich, Munich, Germany) and TMZ (ScheringPlough, Kenilworth, PA) in dimethyl sulfoxide and vincristine (GRY-Pharma, Kirchzarten, Germany) in 0.9% NaCl solution. Doxorubicin (Farmitalia Carlo Erba, Freiburg, Germany) and paclitaxel (Bristol-Myers Squibb) were obtained as solutions. ACNU and BCNU were dissolved directly before use; all other stock solutions were stored at À 20 1C.
Cell culture
The human myeloid leukemia cell lines HL-60 and K562 were cultured in RPMI-1640 medium (Invitrogen, Karlsruhe, Germany) supplemented with 10% fetal calf serum (PAA, Pasching, Austria), penicillin (100 IU ml
; Invitrogen) and streptomycin (100 mg ml 
Viral work and detection of transduced cells
Lentiviral stocks were produced and titrated as described previously. 38 HL-60 and K562 cells were transduced (with an multiplicity of infection of 3) and selected by vincristine (20 nM) or BCNU (40mm) according to standard operating procedures. 31 HSCs were pre-stimulated as described previously; 31 then cells were transduced three times (each with an multiplicity of infection of 10) during 24 h as described previously 31 for experiments shown in Figure 3 or according to the protocol of Santoni de Sio et al. 39 for experiments shown in Figure 4 with Iscove's modified Dulbecco's medium supplemented with 300 ng ml À 1 human stem cell factor, 300 ng ml À 1 fms-like tyrosine kinase receptor-3 ligand, 100 ng ml À 1 thrombopoietin, 60 ng ml À 1 interleukin-3 (all from R&D systems, Wiesbaden, Germany), 8 mg ml À 1 polybrene (Sigma-Aldrich) and 0,75 mM MG-132 (Merck4Biosciences, Darmstadt, Germany). After 48 h, medium was changed (free of polybrene and MG-132). The percentage of cells expressing MDR1 was determined by the rhodamine-123 efflux assay, 40 MGMT-expressing cells were detected by intracellular staining with the anti-MGMT monoclonal antibody mt3.1 (Acris antibodies, Hiddenhausen, Germany). 41 Acquisition was performed on a FACSCalibur flow cytometer (Becton Dickinson), and data were analyzed with the CellQuest software (Becton Dickinson).
Quantitative real-time PCR
Total RNA of about 3-5 Â 10 5 cells was extracted and purified with the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Reverse transcription of 500 ng total RNA was performed with TaqMan Reverse Transcription Reagents (Life Technologies, Darmstadt, Germany). Primers and probes for MGMT P140K and for MDR1 40, 42 were published previously. GAPDH (PE Applied Biosystems, VIC-MGB labeled) was used as reference gene. For determination of vector copy numbers genomic DNA was isolated from up to 1 Â 10 6 HL-60 or K562 cells using the QIAamp DNA Blood Mini Kit (Qiagen) according to the manufacturer's instructions. Standard curves were generated by diluting plasmid DNA containing either a part of the human erythropoietin receptor gene (hEPOR) as a reference or the Woodchuck hepatitis virus posttranscriptional regulatory element sequence in pHR'SIN-MDR1 and using respective primers 43 (Veldwijk MR, unpublished results). All PCR reactions were performed in triplicate using an ABI Prism 7700 sequence detection system (Life Technologies) with the following thermocycling conditions: 50 1C for 2 min, 95 1C for 10 min and then 40 cycles of 15 s at 95 1C and 1 min at 60 1C. Quantification of the transcripts was made by the DDCt method (User Bulletin no. 2, ABI PRISM 7700 Sequence Detection System).
Drug treatment and chemosensitivity assays
After pre-treatment with O 6 -BG (20 mM) for 1 h the alkylating agent (ACNU, BCNU or TMZ) was added for 2 h. Then, cells were incubated in a fresh medium containing only O 6 -BG (20 mM) for another 21 h. Paclitaxel and doxorubicin were either added to cell suspension for 48 h (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay) or for 5 h (liquid culture). For combination therapy treatment with the alkylating agent was done first as indicated for monotherapy. On the following day cells were incubated with paclitaxel or doxorubicin. The subsequent 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was performed by treatment of the cells with serial twofold drug dilutions as described before. 31 Combination doses were adjusted according to the appropriate monotherapy experiments.
Concentrations were each increased by a factor 2; in the following, the lowest and highest concentrations for treatment of HL-60 and K562 cells are given (for concentrations for treatment of HSCs see Figures 3 and 4): ACNU (monotherapy) 10-2560 mM; BCNU (monotherapy) 5-640 mM; paclitaxel (monotherapy) 3.125-800 nM; doxorubicin (monotherapy) 0.3125-40 mM; ACNU/paclitaxel (combination therapy) 10 mM/3.125 nM-640 mM/200 nM; BCNU/doxorubicin (combination therapy) 5 mM/3.125 mM-640 mM/40 mM.
All half-maximal inhibitory concentration (IC 50 ) values were determined using the CalcySyn software (Biosoft, Cambridge, UK), which is based on the median effect method. 44 The chemoprotection of CD34 þ cells was assayed exclusively by flow cytometry. Three days after transduction, cells were seeded into 24-well plates at a density of 5 Â 10 4 cells per 0.5 ml Iscove's modified Dulbecco's medium medium and exposed to varying drug concentrations as described. 31 Afterwards cells were held for 12 days in a liquid culture under myeloidspecific differentiation conditions (Iscove's modified Dulbecco's medium supplemented with 10% fetal calf serum, containing interleukin-1b, interleukin-3, interleukin-6, granulocyte colony-stimulating factor, granulocytemonocytecolony-stimulating factor, stem cell factor, each at a concentration of 10 ng ml À 1 ; R&D systems). Subsequently, the proportions of MGMT-or MDR1-expressing cells were determined by flow cytometry.
The liquid culture is required as human CD34 þ cells endogenously express MDR1, which cannot be distinguished by fluorescence-activated cell sorting (FACS) from the lentiviral MDR1 expression. After differentiation to myeloid cells, the endogenous MDR1 expression is silenced and therefore only transgenic MDR1 expression can be detected by rhodamine-123 assay at that time. 45 
Statistical analysis
As indicated in figure legends results are presented as means±s.d. or s.e. and represent usually three independent experiments. P-values (calculated by the two-sided, paired Welch's t-test (cell lines) or Student's t-test (HSCs)) less than or equal to the significance level 0.05 were designated as statistically significant; the evaluation was based on IC 50 values (MTT assay for K562 and HL-60 cells) or the difference between treated and untreated fraction (FACS for HSCs). Owing to the exploratory nature of the analysis, P-values were not adjusted for multiple testing. The combination of O 6 -BG/BCNU and doxorubicin was used for the chemoprotection analysis in transduced K562 cells (Table 3) . Again, transduction with HR'SIN-MGMT P140K -F2A-MDR1 (no. III) resulted in highly efficient chemoprotection after mono-or combination therapy; the IC 50 values due to transgene expression by HR'SIN-MDR1-IRESEMCV-MGMT P140K (no. VIII) were similarly increased (Po0.01 (for doxorubicin and BCNU) or P ¼ 0.02 (for doxorubicin and BCNU), respectively, versus untransduced cells). (no. VIII) were further evaluated in HSCs as transgene expression with both vectors showed chemoprotection against both regimens in HL-60 and K562 cells. In contrast, transgene expression by vector IV and V failed to result in any chemoprotection of HL-60 cells after treatment with ACNU and paclitaxel, thus, vectors IV, V and its counterpart vector VI were excluded from further analysis in HSCs.
RESULTS

Cloning
The liquid culture proliferation assay in combination with the rhodamine-123 assay was used to evaluate the amount of MDR1-expressing (8transduced cells) and of vital cells as this assay is more accurate for testing chemotherapeutic efficiencies and shows a lower variability in results than a colony-forming assay. 45, 50 Combination of O 6 -BG/BCNU plus doxorubicin was used first (Figure 3 ). The amount of transduced and vital cells was analyzed 1 week after chemotherapeutic treatments. Transduction efficiency without treatment ranged for all three vectors between 0.6 and 4.5%. After drug treatment, the results did not differ significantly for both vectors with the IRES-element of EMCV. 
DISCUSSION
Myeloprotective gene therapy is a promising method to reduce the toxic effects of chemotherapeutics 51 and the risk of therapyassociated neoplasias as use of alkylating agents might result in secondary acute leukemia. 52 Thus, transplantation of ex vivo gene therapeutically modified HSCs would enable subsequent highdose chemotherapy with a reduced risk of myelosuppression and might be more beneficial than a standard autologous transplantation of unmodified HSCs after single high-dose chemotherapy. Gammaretro-or lentiviral transduction of HSCs is already an established technique that has been also applied in clinical trials. 53, 54 As often a combination of various chemotherapeutic drugs affecting different mechanisms and targets is applied clinically, a combination of two transgenes with distinct detoxifying properties would be advantageous. Previously, we demonstrated chemoprotection by overexpression of MDR1 and MGMT P140K encoded by a bicistronic lentiviral vector. 31 However, resistance against alkylating agents (BCNU or TMZ) was less effective than against substrates of MDR1. This might be caused by decreased expression of the MGMT protein as the MGMT P140K cDNA was placed at the second position in the bicistronic expression cassette. Therefore, we cloned five additional bicistronic lentiviral vectors assessing three different linker sequences, F2A, IRESFMDV and IRESEMCV, combining both transgenes placed either as first or second cistron in the expression cassette.
After transduction of the two myeloid cell lines K562 and HL-60 with the various vectors, transcription of MDR1 was found to be not dependent on the position in the cassette or on the linker element used. However, expression of MGMT P140K in K562 in contrast to HL60 cells differed significantly depending on its cDNA placed as first or second cistron using the two different IRES-elements. The use of the F2A-element did not result in a significant expression difference of MGMT P140K or MDR1 in both cell lines suggesting for an equimolar expression of both recombinant proteins owing to the processing of the polypeptide chain.
Thus, the results of MGMT P140K expression correlate with earlier studies demonstrating significantly reduced expression of IRESdependent transgenes than of transgenes in the 5 0 position. 33, 55 Especially for MGMT, it was shown that the IRES-dependent expression in a retroviral vector resulted only in a tenth of active protein compared with CAP-dependent expression. 27 A high expression rate of the MGMT protein is important for efficient dealkylation of O 6 -guanines as each MGMT molecule is irreversibly inactivated after binding of one alkyl group. 8 The transgene itself might influence the IRES-dependent translation owing to its structure or sequence. 56 In addition, an influence of the cell type or of the available cellular components might be possible. 57 The observation that a significant position dependence for MGMT P140K expression under the control of both IRES elements could be found only in K562 but not in HL-60 cells argues for a cell typespecific effect maybe in combination with a ternary structure of the MGMT mRNA.
The functional assay analyzing the rate of chemoprotection of (Figure 4a ). For paclitaxel monotherapy and for combination therapy no difference comparing both vectors could be shown. The increase of transduced cells was up to 495%, demonstrating effective chemoprotection by both resistance genes. Interestingly, we found an initial increase of untransduced cells, which showed enhanced rhodamine efflux after paclitaxel monotherapy or O 6 -BG/TMZ/paclitaxel combination therapy. However, in these populations only few cells survived chemotherapy (only several hundred cells could be analyzed by FACS in contrast to the standard number of 10 000 cells counted in all transduced entities). This suggests that a few untransduced cells expressed endogenous MDR1 even after the liquid culture resulting in increased survival after chemotherapy.
For further clinical use of this bicistronic expression cassette the lentiviral vector should be optimized to meet the increased safety requirements accrued from several cases of myelodysplasia or leukemia following gammaretroviral gene therapy. [58] [59] [60] These hematological disorders were attributed to the so-called insertional mutagenesis which means that the promoter driving the transgenes influences the expression of genes in the host genome in the vicinity of the integrated provirus. Although intense analyses revealed that additional genomic instabilities were involved in the progression of these leukemic clones, 61, 62 further vector improvement is urgently needed. One advantage of lentiviral vectors is their substantially reduced genotoxic risk compared with gammaretroviral vectors. 63 In contrast to gammaretroviral vectors, lentiviral vectors showed a different integration pattern nearly completely omitting a region of 1 kb around the transcription start site. 64 Thus, the risk of an interaction with the promoter activity of an endogenous gene might be reduced. Furthermore, integration analysis in a study with gammaretroviral transfer of MDR1 into HSCs of a patient with breast cancer revealed that after transplantation expansion of MDR1 clones was promoted by treatment with docetaxel but this expansion persisted only for o3 years. 22 A myelodysplastic expansion of a clone was not observed in this patient.
Additional elements to increase the safety profile of the vector are on the one hand insulator elements (like hypersensitive site at the 5 0 end (5 0 HS4) of the chicken b-globin locus 65 ) inhibiting the influence of the viral vector on the endogenous gene expression. On the other hand, the use of a cellular promoter instead of the strong promoter element derived from the LTR sequence of spleen focus-forming virus might further decrease the risk of deregulation of endogenous genes. 66 Comparison of a strong viral and a weaker cellular promoter revealed that use of the cellular promoter resulted in sufficient expression and detoxification efficiency of MGMT P140K protein and in better engraftment of transduced HSCs in mice. 26 Promoter methylation and silencing has been described as a disadvantage of the spleen focus-forming virus promoter, 67 ,68 which we used in our vector. To circumvent this problem, replacement of the spleen focus-forming virus promoter by the methylation-resistant ubiquitous chromatin opening element should enable stable and long-term expression of transgenes in HSCs. 69 Furthermore, this element lacks any enhancer activity, which reduces the risk for insertional mutagenesis as transcriptional activation of endogenous genes adjacent to the vector integration site is not possible. Therefore, we plan to use these insulator and promoter elements in our future vector.
In summary, we could show efficient chemoprotection of HSCs using various bicistronic lentiviral vectors overexpressing MDR1 and MGMT P140K . Comparing all vectors, vector no. III (HR'SIN-MGMT P140K -F2A-MDR1) resulted in the most efficient chemoprotection. Especially, the shortness of a 2A-element with only 72 bp in comparison with 500-600 bp of an IRES-element is advantageous for cloning vectors with limited cloning capacity. Application of such a chemoprotective strategy will enable the increase of the therapeutic index during combination chemotherapies due to a reduction of myelotoxic side effects and eventually due to a dose escalation of chemotherapeutics.
